According to the user type and distribution channel, pharmaceutical e-commerce can be divided into three types: B2B, B2C and O2O, of which B2B serves each B-end of the pharmaceutical industry and occupies the main position
of pharmaceutical e-commerce transactions.
Since 2020, affected by the environment, the way of online drug purchase has gradually been accepted by consumers, and pharmaceutical e-commerce B2B has ushered in rapid growth, with a market size of 207.
2 billion yuan
in 2021.
As an important link connecting upstream pharmaceutical manufacturing enterprises, downstream medical institutions and retail terminals, the pharmaceutical circulation industry plays an important role
in the entire pharmaceutical industry chain.
The industry believes that under the background of the continuous advancement of medical insurance reform, the pharmaceutical circulation industry may face new challenges
.
The Guiding Opinions on Promoting the High-quality Development of the Pharmaceutical Circulation Industry in the 14th Five-Year Plan Period puts forward clear requirements for the high-quality development of China's pharmaceutical circulation industry during the 14th Five-Year Plan period: by 2025, the pharmaceutical circulation industry will be adapted to the health needs of the people in the new stage of China's development, and the modern pharmaceutical circulation system led by innovation, empowered by science and technology, covering urban and rural areas, balanced layout, coordinated development, safe and convenient will be more perfect
。 The overall goal is to cultivate and form 5-10 specialized and diversified pharmaceutical retail chain enterprises of more than 50 billion yuan, the annual sales of the top 100 pharmaceutical retail enterprises account for more than 65% of the total pharmaceutical retail market, and the pharmaceutical retail chain rate is close to 70%.
Some analysts believe that under the catalysis of policies, the trend of standardization and scale of the pharmaceutical circulation industry will be further strengthened, and the head pharmaceutical circulation enterprises are expected to stand out in the market with their competitive advantages such as strong terminal coverage capacity and perfect logistics and transportation network, and will have more imagination space
in the future.
At present, pharmaceutical companies are accelerating their embrace of digital transformation
.
For example, in 2021, CR Pharma will promote the digital transformation and upgrading of its pharmaceutical distribution business, lay out a new track of Internet medical business, and strengthen its professional capabilities in device distribution business.
Sinopharm Holdings continues to increase investment in digital and intelligent transformation, simultaneously carries out the construction of digital transformation projects in the four business formats of pharmaceuticals, devices, retail and logistics, and further promotes the transformation and upgrading of business segments to "professional national integrated services" through the sorting and reshaping of business processes and data assets.
Jointown also said that "in 2022, the company will create a new digital pharmaceutical circulation model by establishing a new pharmaceutical industry supply chain platform"
.
At the same time, capital enthusiasm is also high, and more companies are accelerating their impact on the secondary market
.
On September 14 this year, Dingdang Health was listed
on the main board of the Hong Kong Stock Exchange.
This is also the third pharmaceutical e-commerce listed on the Hong Kong Stock Exchange, which shows that enterprises are optimistic about the prospects of pharmaceutical e-commerce
.
As the pharmaceutical circulation industry takes the "Internet +" express, the industry expects that the scale of China's pharmaceutical e-commerce B2B market will exceed 370 billion yuan by 2025, reaching 375.
8 billion yuan, with a broad
market space.
It is worth mentioning that in the context of digitalization in the field of drug circulation, how to manage the data generated is also an urgent problem
to be solved in the industry.
According to incomplete statistics, there are currently as many as 8 relevant national standards, many places have also introduced their own local regulations, and there are many management standards within the industry, but because they are not mandatory standards, enterprises' cognition of data may be biased, and it is impossible to ensure the compliant application of
data.
In order to comprehensively improve the data governance level of pharmaceutical circulation enterprises, improve the modern drug circulation system, improve the efficiency of drug circulation, and promote the high-quality development of the industry, in December 2021, the "Master Data Management Standard for Pharmaceutical Circulation Terminal Institutions" led by the China Pharmaceutical Commerce Association and jointly compiled by 18 pharmaceutical circulation enterprises has been released
.
Standards will help solve the problem of inconsistent standards, data, and interfaces in the upstream and downstream of the industry, and greatly improve the data management and collaboration efficiency of
enterprises.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
